Extendicare (TSE:EXE - Get Free Report) had its price objective increased by research analysts at BMO Capital Markets from C$13.50 to C$14.50 in a report released on Monday,BayStreet.CA reports. BMO Capital Markets' price objective suggests a potential upside of 0.42% from the company's current price.
Several other analysts also recently commented on the stock. TD Securities raised their price objective on shares of Extendicare from C$10.50 to C$13.00 and gave the company a "hold" rating in a research report on Monday, March 3rd. Cormark upgraded shares of Extendicare to a "moderate buy" rating in a report on Wednesday, February 19th.
Check Out Our Latest Report on EXE
Extendicare Stock Performance
EXE stock traded up C$0.11 on Monday, hitting C$14.44. The company had a trading volume of 141,035 shares, compared to its average volume of 190,807. Extendicare has a 12-month low of C$7.10 and a 12-month high of C$15.24. The company has a current ratio of 0.62, a quick ratio of 0.98 and a debt-to-equity ratio of 283.02. The stock's 50-day simple moving average is C$13.24 and its 200 day simple moving average is C$11.40. The stock has a market cap of C$1.21 billion, a price-to-earnings ratio of 18.41 and a beta of 1.26.
About Extendicare
(
Get Free Report)
Extendicare Inc, operating solely in Canada, is the largest private-sector owner and operator of long-term care (LTC") homes and one of the largest private-sector providers of publicly funded home health care services.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Extendicare, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Extendicare wasn't on the list.
While Extendicare currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
